Pharmaceuticals
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
HONG KONG, Jan. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE) of the N...
2025-01-27 09:53
3385
CARiNG Pharmacy Celebrates Consecutive Gold Triumph at the 2024 Putra Aria Brand Awards
KUALA LUMPUR, Malaysia, Jan. 27, 2025 /PRNewswire/ -- CARiNG Pharmacy is thrilled to announce its back-to-back victory in securing the Gold award in the retail category at the 2024 Putra Aria Brand Awards. This recognition highlights the brand's unwavering commitment to excellence in the retail ...
2025-01-27 08:33
4387
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 25, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infectio...
2025-01-25 02:00
6696
Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors
SINGAPORE and PHILADELPHIA, Jan. 24, 2025 /PRNewswire/ -- Nuevocor
2025-01-24 22:00
6406
Kexing Biopharm Participates in the 17th Biotech Showcase, with Multiple Innovation Pipelines Gaining Attention
SHENZHEN, China, Jan. 24, 2025 /PRNewswire/ -- From January 13 to 16, Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase Conference inSan Francisco and the Global Biopharma Symposium hosted by Jones Day & MSQ Ventures. The Jones...
2025-01-24 14:59
4771
Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC
CHENGDU, China, Jan. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization inChina from National Medical Products Administration (NMPA) for the programmed cell death ligand 1(PD-L1)-directed innovativ...
2025-01-23 13:44
3963
GC Cell Symposium with Bifarma Expands Global Impact and Reach for Immuncell-LC
YONGIN, South Korea, Jan. 23, 2025 /PRNewswire/ -- GC Cell
2025-01-23 09:30
3347
Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine
HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")is excited to announce that the prestigious medical journal Nature Medicine published the results of the company's independently developed PD-1/CTLA-4 bispecific antibody cadonilimab in combination with oxali...
2025-01-23 08:31
2915
TraceLink Named to the 2025 RXinsider Pharmacy500 List for Excellence in Pharmacy Supply Chain Innovation
TraceLink recognized for advancing digitalization and orchestration in the pharmacy supply chain, ensuring safe and timely access to medications BOSTON, Jan. 22, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, is honored ...
2025-01-22 23:00
3119
GI Innovation-LaNova Medicines Signs MOU for GI-102 + ADC Pancreatic Cancer Combination Therapy
SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- GI Innovation
2025-01-22 21:00
4117
L&C Bio Secures World's First NMPA Approval for 'MegaDerm Plus' in China
SEONGNAM-SI, South Korea, Jan. 22, 2025 /PRNewswire/ -- L&C Bio (CEO Hwan-Chul Lee) has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval fromChina's National Medical Products Administration (NMPA) for its acellular dermal ma...
2025-01-22 20:30
3891
JelloX Aims to Improve Patient-Centered Care with AI-powered 3D Digital Pathology
First shared at a recent Japanese Society of Digital Pathology meeting, the
company is forging a global alliance with a leading US medical institution and
other organizations to harness technology for better patient care and outcomes
in oncology.
TAIPEI, Jan. 22, 2025 /PRNewswire/ -- JelloX
2025-01-22 15:29
4153
Samsung Biologics reports fourth quarter and fiscal year 2024 financial results
* Recorded Q4'24 consolidated revenue of KRW 1.26 trillion * Recorded FY'24 consolidated revenue of KRW 4.55 trillion * Poised for further growth with expanded capacity and new service offerings INCHEON,South Korea, Jan. 22, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a globa...
2025-01-22 15:06
3368
Akeso Received Payment for the Development Collaboration on Tagitanlimab
HONG KONG, Jan. 22, 2025 /PRNewswire/ -- On January 22, 2025, Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun") for their collaboration on the development of tagitanlimab, an innovative humanized monoclona...
2025-01-22 14:57
4065
Hyundai ADM Unveils a "New Paradigm in Cancer Treatment" - Preclinical Study Shows Promise for Continuous Oral Chemotherapy with Lowered Side Effects Risks
SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- Hyundai ADM Bio (Co-CEOs Taek-Sung Kim and Kwang-Hee Kim) announced the results of its preclinical study on the oral anti-cancer drug OTX-M, developed from the well-known injectable chemotherapy drug docetaxel, at the "Biotech Showcase 2025" held ...
2025-01-22 14:43
5435
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers
HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Today, Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement withArriVent BioPharma, Inc. for MRG007, a Potential Best-in-Class antibody- drug conjugate ("ADC") for the treatment of Gastrointesti...
2025-01-22 12:19
5223
Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025
BOSTON, Jan. 21, 2025 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced the presentation of latest data from its Phase I/II CLINCH study ongoing in China and Australia evaluating ATN-022 (CLDN18.2 antibody-drug conjugate [ADC]) in patients with advance...
2025-01-22 11:01
3010
Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update
* ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supporting once-daily or less frequent oral dosing. * ASC30 oral tablet was generally safe and well ...
2025-01-21 19:00
5682
TAHO Pharmaceuticals Completes Pivotal Trial of TAH3311, the First Oral Dissolving Film Anticoagulant
TAIPEI, Jan. 21, 2025 /PRNewswire/ -- TAHO Pharmaceuticals is pleased to announce the successful completion of the pivotal trial for TAH3311, the first anticoagulant oral dissolving film (ODF). This trial was conducted following detailed discussions and alignment with the U.S. Food and Drug Admin...
2025-01-21 15:30
2824
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia
SHANGHAI, Jan. 20, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial forYOLT-204, an investigational therapy for the treatment of transfusion-dependent beta-thalassemia (TDT). TDT i...
2025-01-21 10:34
3379
Week's Top Stories
Most Reposted
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 301 media titles]
2026-08-06 15:10
GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 296 media titles]
2026-08-12 16:02
MetaOptics Ltd achieves 79% of FY2025 full-year revenue in 1H 2026, on track to fulfil purchase orders of key metalens production equipment in 2H 2026
[Picked up by 293 media titles]
2026-08-11 19:03Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 292 media titles]
2026-08-10 19:12
Most Read
Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
2026-08-06 15:10
18249
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
12278
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
12098